Cargando…

Management of bipolar I depression: clinical utility of lurasidone

Lurasidone is a benzisothiazol derivative second-generation antipsychotic. It has been approved in the United States and Europe for treatment of acute schizophrenia and bipolar depression. In type I bipolar subjects, treatment with lurasidone monotherapy of adjunctive therapy to lithium or valproic...

Descripción completa

Detalles Bibliográficos
Autores principales: Findlay, Lillian Jan, El-Mallakh, Peggy, El-Mallakh, Rif S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293929/
https://www.ncbi.nlm.nih.gov/pubmed/25609973
http://dx.doi.org/10.2147/TCRM.S57695
_version_ 1782352677338873856
author Findlay, Lillian Jan
El-Mallakh, Peggy
El-Mallakh, Rif S
author_facet Findlay, Lillian Jan
El-Mallakh, Peggy
El-Mallakh, Rif S
author_sort Findlay, Lillian Jan
collection PubMed
description Lurasidone is a benzisothiazol derivative second-generation antipsychotic. It has been approved in the United States and Europe for treatment of acute schizophrenia and bipolar depression. In type I bipolar subjects, treatment with lurasidone monotherapy of adjunctive therapy to lithium or valproic acid with doses of 20 to 120 mg once daily with food, results in statistically and clinically significant reduction of depressive symptoms. Patients experience relatively few side effects, which include somnolence, akathisia, nausea, and other gastrointestinal upset. Dopamine related side effects, such as Parkinsonism and elevated prolactin, are rare and mild. Longer term safety data obtained in 6 months long, open continuation observation periods, suggest that metabolic related elevations in weight, glucose, and lipids are absent or minimal. The mechanism of action of lurasidone is not known, but the data are compatible with antagonism of the serotonin 7 receptor. Lurasidone is a new option for the treatment of bipolar depression with relatively few side effects.
format Online
Article
Text
id pubmed-4293929
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-42939292015-01-21 Management of bipolar I depression: clinical utility of lurasidone Findlay, Lillian Jan El-Mallakh, Peggy El-Mallakh, Rif S Ther Clin Risk Manag Review Lurasidone is a benzisothiazol derivative second-generation antipsychotic. It has been approved in the United States and Europe for treatment of acute schizophrenia and bipolar depression. In type I bipolar subjects, treatment with lurasidone monotherapy of adjunctive therapy to lithium or valproic acid with doses of 20 to 120 mg once daily with food, results in statistically and clinically significant reduction of depressive symptoms. Patients experience relatively few side effects, which include somnolence, akathisia, nausea, and other gastrointestinal upset. Dopamine related side effects, such as Parkinsonism and elevated prolactin, are rare and mild. Longer term safety data obtained in 6 months long, open continuation observation periods, suggest that metabolic related elevations in weight, glucose, and lipids are absent or minimal. The mechanism of action of lurasidone is not known, but the data are compatible with antagonism of the serotonin 7 receptor. Lurasidone is a new option for the treatment of bipolar depression with relatively few side effects. Dove Medical Press 2015-01-08 /pmc/articles/PMC4293929/ /pubmed/25609973 http://dx.doi.org/10.2147/TCRM.S57695 Text en © 2015 Findlay et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Findlay, Lillian Jan
El-Mallakh, Peggy
El-Mallakh, Rif S
Management of bipolar I depression: clinical utility of lurasidone
title Management of bipolar I depression: clinical utility of lurasidone
title_full Management of bipolar I depression: clinical utility of lurasidone
title_fullStr Management of bipolar I depression: clinical utility of lurasidone
title_full_unstemmed Management of bipolar I depression: clinical utility of lurasidone
title_short Management of bipolar I depression: clinical utility of lurasidone
title_sort management of bipolar i depression: clinical utility of lurasidone
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293929/
https://www.ncbi.nlm.nih.gov/pubmed/25609973
http://dx.doi.org/10.2147/TCRM.S57695
work_keys_str_mv AT findlaylillianjan managementofbipolaridepressionclinicalutilityoflurasidone
AT elmallakhpeggy managementofbipolaridepressionclinicalutilityoflurasidone
AT elmallakhrifs managementofbipolaridepressionclinicalutilityoflurasidone